NASDAQ:CTXR   Citius Pharmaceuticals, Inc.
test
評論:
updating today
評論:
The terminal corrective point for CTXR is this month. The max drawdown is about -30% from here if we fell more, which would be a blessing...since the upside is $5+ or about +462% from here. Accumulate accumulate accumulate
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。